Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves a ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are underva ...

Puma Biotechnology (PBYI) reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a loss of 5 cents per share.The above-adjusted earnings exclude the impact of stock-based compensation expense. Including the same, earnings per share were 6 cents against a loss of 10 cents in the year-ago quarter.Total revenues were $46.0 million, which also beat the Zacks Consensus Estimate of $44.0 million.Rev ...

Puma Biotechnology Earnings Call Commercial Update May 8, 2025 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statem ...

Puma Biotech (PBYI) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 400%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.14 per share when it actually produced earnings of $0.43, delivering a surprise of 207.14%.Over the last four quarters, th ...

Puma Biotechnology (PBYI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Mariann Ohanesian - Senior Director of Investor RelationsAlan Auerbach - Founder, Chairman, President, CEO & SecretaryJeffrey Ludwig - Chief Commercial OfficerHeather Blaber - VP - MarketingRoger Storms - VP - SalesMaximo F. Nougues - CFO & Principal Accounting Officer Conference Call Participants Divya Rao - AnalystNone - Analyst Operator Good afternoon. My name is Sherry, and I will be your conference call operat ...

Puma Biotechnology (PBYI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon. My name is Sherry, and I will be your conference call operator today. At this time, all participants are in a listen only mode. After the speakers' formal remarks, there will be a question and answer session. As a reminder, this call is being recorded. I would now like to turn the conference over to Mary Anne O'Hanison, Senior Director of Investor Relations for Puma Biotechnology. Thank you. You may begin your ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State or othe ...

Financial Performance - Product revenue for Q1 2025 was $43.1 million, a 6.9% increase from $40.3 million in Q1 2024[3] - Net income for Q1 2025 was $3.0 million, compared to a net loss of $4.8 million in Q1 2024, marking a significant turnaround[4] - Non-GAAP adjusted net income for Q1 2025 was $5.0 million, compared to a non-GAAP adjusted net loss of $2.4 million in Q1 2024[5] - Total revenue for Q1 2025 was $46.0 million, compared to $43.8 million in Q1 2024, reflecting a 5.0% increase[8] - Basic and diluted net income per share for Q1 2025 was $0.06, compared to a loss of $0.10 per share in Q1 2024[29] - Non-GAAP adjusted basic net income per share for Q1 2025 was $0.10, compared to a loss of $0.05 per share in Q1 2024[34] Operating Costs - Total operating costs and expenses decreased to $42.0 million in Q1 2025 from $46.1 million in Q1 2024, a reduction of 8.9%[9] - Selling, general and administrative expenses decreased by $4.2 million to $17.6 million in Q1 2025, primarily due to lower professional fees[11] - Research and development expenses slightly increased to $13.8 million in Q1 2025 from $13.6 million in Q1 2024[13] - Stock-based compensation represented approximately 6.4% of operating expenses in Q1 2025, slightly down from 6.7% in Q1 2024[32] Cash and Liquidity - Cash, cash equivalents, and marketable securities totaled $93.2 million as of March 31, 2025, down from $101.0 million at the end of 2024[6] - Cash and cash equivalents as of March 31, 2025, were $63.0 million, down from $69.2 million as of December 31, 2024[31] - The company reported a net decrease in cash, cash equivalents, and restricted cash of $6.2 million for the three months ended March 31, 2025[31] Future Outlook - The company anticipates net product revenue for Q2 2025 to be between $48 million and $50 million, and for the full year 2025 to be between $192 million and $198 million[15] - Key upcoming milestones include interim data presentations from ongoing clinical trials in H2 2025[7]

Puma Biotech (PBYI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individ ...